EIKN (NASDAQ:EIKN) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of EIKN (NASDAQ:EIKN) from a hold rating to a sell rating in a research note issued to investors on Sunday.

Several other analysts have also issued reports on the company. Mizuho began coverage on EIKN in a report on Monday, March 2nd. They set an “outperform” rating and a $26.00 target price on the stock. Morgan Stanley initiated coverage on shares of EIKN in a research report on Monday, March 2nd. They set an “overweight” rating and a $32.00 price target on the stock. JPMorgan Chase & Co. initiated coverage on shares of EIKN in a research note on Monday, March 2nd. They issued an “overweight” rating and a $29.00 price objective on the stock. Wedbush reissued an “underperform” rating and issued a $7.00 price objective on shares of EIKN in a research note on Tuesday, March 31st. Finally, Cantor Fitzgerald initiated coverage on shares of EIKN in a research note on Monday, March 2nd. They issued an “overweight” rating on the stock. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, EIKN presently has a consensus rating of “Moderate Buy” and an average price target of $25.60.

EIKN Stock Performance

EIKN opened at $8.78 on Friday. EIKN has a 52-week low of $8.65 and a 52-week high of $17.40.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.